List of Excipients in Branded Drug JYNARQUE

« Back to Dashboard

Jynarque Excipient Strategy and Commercial Opportunities for Tolvaptan Tablets

Last updated: September 27, 2026

Jynarque is an oral tolvaptan tablet approved by the FDA for adults at risk of rapidly progressing autosomal dominant polycystic kidney disease, or ADPKD. Its excipient platform is conventional and low-cost, but the product creates commercial opportunities in generic formulation development, moisture-controlled packaging, dose-pack design, supply security, and differentiated delivery systems. The primary technical barriers are bioequivalence across five strengths, tablet robustness, lactose management, stability under chronic-use conditions, and regulatory controls associated with the Jynarque REMS program.

What is Jynarque and how is it administered?

Jynarque contains tolvaptan, a selective vasopressin V2-receptor antagonist. The product is supplied as immediate-release tablets in five strengths:

Strength	Typical role in dose titration
15 mg	Lower component of the initial 60 mg split dose
30 mg	Lower component of the target 90 mg split dose
45 mg	Morning component of the initial 60 mg split dose
60 mg	Morning component of the target 90 mg split dose
90 mg	Available strength, generally used as a morning dose component

Treatment begins at 60 mg per day, administered as 45 mg in the morning and 15 mg approximately eight hours later. The dose may be increased to 90 mg per day, administered as 60 mg in the morning and 30 mg later in the day. Patients must have access to water and are instructed to respond to thirst because tolvaptan increases aquaresis rather than conventional diuresis. [1]

Jynarque is approved only for adults at risk of rapidly progressing ADPKD. The FDA requires liver-function monitoring and restricts distribution through a Risk Evaluation and Mitigation Strategy, or REMS, because of the risk of serious and potentially irreversible liver injury. [1, 2]

What excipients are used in Jynarque tablets?

The Jynarque formulation uses common tablet excipients rather than a proprietary controlled-release or lipid-based delivery system. Public labeling identifies the core excipient platform as:

• Lactose monohydrate
• Corn starch
• Hydroxypropyl cellulose
• Low-substituted hydroxypropyl cellulose
• Magnesium stearate
• Tablet colorants, depending on strength

The exact colorant system varies by tablet strength and appearance. The FDA-approved labeling and DailyMed product information should control any formulation comparison or regulatory filing. [1, 3]

What does each excipient do?

Excipient	Functional purpose	Commercial and technical relevance
Lactose monohydrate	Diluent and compressibility aid	Creates dairy-derived excipient and lactose-intolerance considerations
Corn starch	Filler and disintegrant	Supports rapid tablet breakup and low-cost manufacturing
Hydroxypropyl cellulose	Binder and processing aid	Influences granule strength, tablet hardness, and dissolution
Low-substituted hydroxypropyl cellulose	Disintegrant	Supports immediate release across multiple strengths
Magnesium stearate	Lubricant	Controls ejection and tooling behavior but can affect wetting and dissolution if overused
Colorants	Product identification	Important for dose differentiation and medication-error prevention

The formulation is commercially attractive because it relies on globally available, compendial materials. It does not require an expensive polymer matrix, specialized coating equipment, sterile processing, or cold-chain distribution.

What excipient strategy is most suitable for generic tolvaptan?

The lowest-risk strategy is a compositionally similar, immediate-release tablet using the same functional excipient classes. A generic developer should prioritize dissolution and tablet performance over exact qualitative and quantitative matching where the ANDA pathway permits formulation differences.

Key development objectives include:

1. Matching dissolution across all five strengths.
2. Preserving rapid disintegration despite high lubricant exposure.
3. Maintaining tablet strength during packaging and transport.
4. Avoiding excessive formulation differences between strengths.
5. Supporting a scalable wet- or dry-granulation process.
6. Demonstrating chemical and physical stability under ICH conditions.

Tolvaptan is a high-value chronic-use product, so small changes in excipient grade, particle-size distribution, moisture content, or lubrication time can affect manufacturing performance. The most important variables are likely to include:

• Lactose particle size and monohydrate grade
• Starch moisture and swelling behavior
• Hydroxypropyl cellulose viscosity grade
• Low-substituted hydroxypropyl cellulose substitution level and particle size
• Magnesium stearate concentration and blending time
• Compression force and tablet porosity
• Colorant dispersion
• Packaging moisture transmission rate

An ANDA applicant should develop a formulation that remains within a narrow dissolution profile across commercial-scale batches. The dose range creates a particular challenge because the 15 mg and 90 mg tablets must provide consistent performance despite different drug-to-excipient ratios.

What formulation patents protect Jynarque?

Jynarque’s publicly described tablet formulation is based on conventional excipients, and the product label does not identify an excipient-specific delivery technology. The commercial protection around Jynarque has historically been more closely associated with tolvaptan composition, therapeutic use, regulatory exclusivity, and product-specific rights than with a novel excipient platform.

A patent review should separate four categories:

Protection category	Relevance to Jynarque
Tolvaptan compound patents	May protect the active ingredient or chemical form
Pharmaceutical composition patents	May cover tablet compositions or dosage forms
Method-of-use patents	May cover treatment of ADPKD or slowing kidney-volume progression
Manufacturing patents	May cover synthesis, purification, or solid-state processing

Excipient suppliers should not assume that use of a conventional lactose-starch-cellulose formulation is free from patent risk. Patent claims can capture quantitative ranges, specific grades, dissolution performance, dosage regimens, or combinations of excipients even when the individual ingredients are old.

At the same time, conventional excipients provide design-around flexibility. A competing formulation may use mannitol, microcrystalline cellulose, calcium phosphate, crospovidone, croscarmellose sodium, or a different cellulose binder, provided it satisfies regulatory and bioequivalence requirements.

When does Jynarque lose exclusivity?

Jynarque received FDA approval in April 2018 for ADPKD under NDA 204001. The product also received orphan-drug designation for the ADPKD indication. Orphan exclusivity generally lasts seven years from approval, subject to the scope of the designation and applicable FDA determinations. That period would generally place the end of ADPKD orphan exclusivity in April 2025. [2, 4]

Orphan exclusivity is separate from patent protection. A generic applicant may face different barriers depending on:

• Remaining Orange Book-listed patents
• Patent-term adjustments or extensions
• Pediatric exclusivity
• Method-of-use claims
• Paragraph IV litigation
• FDA approval of the proposed labeling
• REMS requirements
• Product-specific regulatory exclusivity

The end of orphan exclusivity does not automatically authorize an unrestricted generic launch. Patent certification and litigation outcomes remain controlling.

What is the Orange Book status of Jynarque?

The FDA Orange Book identifies approved drug products and applicable patent and exclusivity information. Jynarque is associated with NDA 204001, while Samsca, another tolvaptan product from Otsuka, is associated with a separate NDA and a different indication profile. [4, 5]

The distinction matters because:

• Jynarque is approved for ADPKD.
• Samsca is used for certain hyponatremia indications.
• The indications, labeling, dosing, and regulatory restrictions are not interchangeable.
• A generic applicant seeking ADPKD approval must address the Jynarque labeling and any protected method of use.
• A generic product approved for another tolvaptan indication may not automatically be substitutable for Jynarque.

Orange Book review should be performed by NDA, patent-use code, and dosage form. A launch assessment based only on the active ingredient or the Samsca listing can produce an incorrect conclusion.

What Paragraph IV challenges and litigation affect Jynarque?

A Paragraph IV certification asserts that an Orange Book-listed patent is invalid, unenforceable, or will not be infringed by the proposed generic. If a generic applicant files a Paragraph IV certification against a Jynarque-listed patent, the patent owner may bring an infringement action within 45 days. A timely action can trigger a statutory stay of FDA approval for up to 30 months, subject to court and regulatory developments. [6]

For Jynarque, litigation risk is likely to concentrate in three areas:

Method-of-use claims

ADPKD treatment claims may create risk even if the generic tablet uses a different excipient system. A product labeled for a protected indication can raise induced-infringement concerns. Carve-out labeling may be commercially important, but it must be consistent with FDA requirements and the scope of the patent claims.

Dose-regimen claims

Claims covering titration schedules, split dosing, or administration in patients with rapidly progressing disease can affect labeling strategy. The five-strength product architecture makes dose-regimen claims commercially relevant.

Manufacturing and solid-state claims

Tolvaptan manufacturing patents can affect active pharmaceutical ingredient sourcing even if the finished dosage-form formulation is non-infringing. A finished-product developer should conduct separate freedom-to-operate reviews for API synthesis, polymorphs, crystallinity, purification, and tablet manufacture.

No excipient-specific Jynarque litigation should be inferred from the public product label. Litigation status must be checked against current federal court records, FDA Orange Book updates, and applicable patent registers.

How strong is the Jynarque patent estate?

The estate is strongest where it combines an ADPKD-specific method of use with regulatory controls and a specialized commercial indication. It is weaker from an excipient perspective because the publicly disclosed dosage form relies on established immediate-release tablet technology.

Estate element	Relative strength
Tolvaptan active ingredient	Depends on remaining patent term and claim scope
ADPKD method of use	Commercially important because of Jynarque’s indication
Five-strength dosing architecture	Relevant to substitution and labeling
Conventional excipients	Generally limited differentiation
REMS and liver monitoring	Regulatory barrier rather than patent protection
Manufacturing process	Potentially important for API and quality consistency
Orphan exclusivity	Time-limited and indication-specific

The strongest generic defense is usually a differentiated excipient composition paired with a robust non-infringement position and an approved labeling strategy. The strongest innovator defense is a combination of method-of-use patents, product-specific listings, and control of the REMS process.

What commercial opportunities exist in Jynarque excipients?

1. Generic formulation development

The largest opportunity is supplying excipients and formulation services to generic tolvaptan developers. Demand can extend across all five strengths and may require multiple manufacturing sites because the product is intended for chronic administration.

Suppliers with value propositions in particle-size control, low-moisture grades, direct compression, and rapid disintegration have the best fit.

2. Co-processed excipients

A co-processed lactose-cellulose or mannitol-cellulose platform could reduce formulation-development time. Potential benefits include:

• Better flow into small-dose tablet dies
• More consistent compactability
• Lower lubricant sensitivity
• Reduced tablet-weight variation
• Easier scale-up across multiple strengths

The developer must demonstrate that the co-processed system does not create a clinically meaningful dissolution difference or require a new dosage-form justification.

3. Lactose-free alternatives

A lactose-free formulation could target patients with lactose intolerance and simplify sourcing for manufacturers that avoid dairy-derived materials. Mannitol, microcrystalline cellulose, dibasic calcium phosphate, and selected starch systems are possible alternatives.

The commercial benefit is limited unless the alternative improves manufacturing, tolerability, or supply security. Lactose removal alone is unlikely to justify a premium product without a clear clinical or operational advantage.

4. Dose-pack and adherence systems

The 60 mg and 90 mg split-dose regimens create an opportunity for calendar packaging, blister cards, and strength-specific adherence packs. A pack could organize the morning and later doses while displaying water-intake and monitoring instructions consistent with approved labeling.

This opportunity is more likely to generate value through adherence and dispensing efficiency than through a new excipient.

5. Moisture-barrier packaging

Tolvaptan tablets require packaging that protects physical integrity and dissolution performance. High-barrier blister films, desiccant systems, and low-moisture bottles can reduce risk during long-term storage.

Packaging suppliers can differentiate through:

• Low water-vapor transmission
• Unit-dose protection
• Child-resistant designs
• Dose differentiation
• Reduced tablet breakage
• Compatibility with specialty-pharmacy distribution

6. Pediatric and geriatric formulation platforms

Jynarque is approved for adults, so pediatric commercialization would require separate clinical and regulatory work. A lower-dose, dispersible, or multiparticulate formulation could have strategic value if the indication expands.

For older adults with chronic kidney disease, swallowability and dose identification may be more commercially relevant than a new active ingredient. Orally disintegrating tablets or smaller tablets would require careful evaluation because the prescribed regimen depends on precise split dosing.

How does Jynarque compare with competing ADPKD treatments?

Product or strategy	Active therapy	Delivery and excipient opportunity
Jynarque	Tolvaptan	Immediate-release tablets, five strengths, high adherence and monitoring burden
Generic tolvaptan	Tolvaptan	Cost reduction, formulation design-around, packaging and supply-chain opportunities
Supportive ADPKD therapy	Multiple agents	Usually does not slow disease progression in the same manner as tolvaptan
Investigational disease-modifying drugs	Various mechanisms	Potential future competition, but formulation and regulatory status vary

Jynarque remains differentiated by its disease-modifying ADPKD indication, but its commercial use is constrained by liver monitoring, aquaretic effects, thirst, polyuria, and REMS obligations. A generic product that matches efficacy while improving packaging, tablet identification, or supply reliability could compete effectively without introducing a novel excipient technology.

What FDA regulatory issues affect excipient commercialization?

A generic tolvaptan product must address more than tablet composition. The development program should account for:

• ANDA requirements under the FDA’s abbreviated pathway
• Pharmaceutical equivalence
• Bioequivalence
• Comparative dissolution
• Stability and impurity control
• Labeling and indication carve-outs
• REMS or comparable safe-use obligations
• Manufacturing-site qualification
• Excipient suitability under FDA inactive-ingredient principles

The FDA’s Inactive Ingredient Database can support precedent analysis, but prior use of an excipient in another product does not eliminate the need to justify its level, route, dosage form, and patient exposure. [7]

For chronic ADPKD treatment, commercial success will depend on uninterrupted supply and consistent tablet performance. Excipient suppliers should therefore provide multi-region regulatory documentation, pharmacopoeial compliance, residual-solvent data, elemental-impurity controls, allergen statements, and change-notification commitments.

What generic launch scenarios exist for Jynarque?

Three launch scenarios are commercially relevant:

Scenario	Description	Excipient implications
Authorized or early entry	Launch follows settlement, license, or favorable patent outcome	Rapid scale-up and supply assurance are critical
At-risk launch	Launch occurs before final patent resolution	Formulation must support a strong non-infringement position
Post-exclusivity entry	Launch follows expiration of relevant exclusivity and patents	Price competition increases; excipient cost and manufacturing yield dominate

The post-exclusivity market is likely to favor formulations with low manufacturing cost, simple supply chains, and reliable performance across all five strengths. Premium excipient systems would need to deliver measurable benefits such as higher yield, lower rejection rates, improved stability, or simplified packaging.

What are the key geographic opportunities?

The United States is the highest-value jurisdiction for Jynarque-related excipient and generic-formulation work because of the product’s FDA approval, REMS structure, and specialty-pharmacy economics.

Other markets may offer opportunities where tolvaptan is used for ADPKD under different brand names or regulatory pathways. Geographic expansion requires separate evaluation of:

• Local product registrations
• Patent and supplementary-protection certificates
• National reimbursement
• Excipient monographs
• Manufacturing localization requirements
• Pharmacovigilance obligations
• Product naming and dose conventions

A supplier with dual compendial capability under USP-NF and Ph. Eur. standards can reduce regional qualification time.

Key Takeaways

• Jynarque is an immediate-release tolvaptan tablet in five strengths: 15, 30, 45, 60, and 90 mg.
• The public formulation uses conventional excipients, including lactose monohydrate, corn starch, hydroxypropyl cellulose, low-substituted hydroxypropyl cellulose, and magnesium stearate.
• The strongest excipient opportunities are generic formulation supply, co-processed excipients, moisture-barrier packaging, and adherence-oriented dose packs.
• Jynarque’s principal commercial barriers are REMS obligations, liver monitoring, chronic-use supply requirements, method-of-use patents, and bioequivalence across multiple strengths.
• Orphan exclusivity for the ADPKD indication generally ran for seven years from the April 2018 approval, placing the expected endpoint in April 2025, subject to the FDA’s specific exclusivity record.
• Excipient innovation alone is unlikely to support a premium product unless it improves dissolution, stability, manufacturability, adherence, or supply security.

FAQs

Can lactose-free excipients be used in a generic Jynarque formulation?

Yes. A generic developer may use a lactose-free diluent system if the formulation meets FDA requirements for pharmaceutical equivalence, bioequivalence, stability, and dissolution. Mannitol, microcrystalline cellulose, and calcium phosphate are potential alternatives.

Does Jynarque require a modified-release excipient system?

No. Jynarque is labeled as an immediate-release tablet. A modified-release formulation would be a substantially different dosage form and could require a separate regulatory strategy.

Is magnesium stearate a major formulation risk for tolvaptan tablets?

It can be. Excessive magnesium stearate or over-lubrication may reduce tablet wetting and alter dissolution. Lubricant level and blending time should be controlled during scale-up.

Can an excipient supplier sell directly into the Jynarque market?

Yes. The most practical customers are generic pharmaceutical companies, contract development and manufacturing organizations, specialty-packaging suppliers, and regional finished-dose manufacturers. Supplier qualification will require robust quality, change-control, and regulatory documentation.

Does the Jynarque REMS apply to excipient manufacturers?

No. The REMS applies to the approved drug’s prescribing, dispensing, monitoring, and distribution system. Excipient manufacturers are not REMS participants, but their materials must support the quality and consistency of the finished product.

References

1. U.S. Food and Drug Administration. (2023). Jynarque (tolvaptan) tablets, for oral use: Prescribing information.
2. U.S. Food and Drug Administration. (2018). FDA approves treatment to slow kidney function decline in adults with autosomal dominant polycystic kidney disease.
3. National Library of Medicine. (2024). Jynarque- tolvaptan tablet, film coated: DailyMed drug label.
4. U.S. Food and Drug Administration. (2024). Drugs@FDA: Jynarque NDA 204001.
5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
6. U.S. Food and Drug Administration. (2023). ANDA submissions: Refuse-to-receive standards and patent certifications.
7. U.S. Food and Drug Administration. (2024). Inactive ingredient database.